PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (15,19–22). Whereas HEY-CTLshRNA cells were practically insensitive to APR-246, HEY-CIP2AshRNA cells showed a >50% reduction in cell viability (Fig. 1A).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [15]
In the citing paper
“The small molecule APR-246 (PRIMA-1Met) can reactive mutant p53 in tumor cells and trigger cell death by apoptosis.”
From Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 (2018) · cites this paper as [7]
In the citing paper
“Importantly, PRIMA-1 and its structural analog PRIMA-1MET (APR-246) inhibited tumor growth in mouse models of GBM [124,129,130].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [129]
In the citing paper
“Although APR-246 was originally identified as a compound that reactivates mutant TP53 (15,16,20), the tested OvCa cell lines displaying hypersensitivity to APR-246 upon CIP2A inhibition, exhibit varying TP53 mutation statuses.”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [15]
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (14)(15)(16)(17)(18).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [15]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“In addition, p53 can transrepress some genes, for instance the antiapoptotic Bcl-2 gene, the IGF1 receptor, MAP4, and hTERT (Vogelstein et al., 2000).”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192 · cited 1×
“…protein induces cell cycle arrest and/or cell death by apoptosis in response to various forms of cellular stress, for example, DNA damage and oncogene activation (Vousden and Lu, 2002). p53 elicits these responses through transcriptional regulation of a large number of downstream effector genes.”
BackgroundAn Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183 · cited 1×
“Likewise, several clinical studies have indicated that anticancer drugs preferentially target wild-type p53carrying breast tumors (Bergh et al., 1995; O’Connor et al., 1997; Weinstein et al., 1997; Borresen-Dale, 2003).”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 4×
“Our previous studies indicated that tumor cells expressing high levels of mutant p53 are more sensitive to PRIMA-1 (Bykov et al., 2002a).”
BackgroundInfluentialSelf-citationDisruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“Studies in cultured human tumor cells and various mouse tumor models have shown that inactivation of p53 reduces or abrogates the apoptotic response to chemotherapy (Bunz et al., 1999; Keshelava et al., 2001; Schmitt, 2003).”
BackgroundPharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799 · cited 9×
“Interestingly, CP-31398 that was shown to induce p53 levels through inhibition of p53 ubiquitination (Wang et al., 2003) induced mutant p53 levels and phosphorylation of p53 at Ser15 in H1299-His175 cells and showed synergy with PRIMA-1MET in mutant p53-expressing cells.”
BackgroundInfluentialThe p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 765 · cited 1×
“The p53-induced MDM2 gene regulates p53 turnover via a negative feedback loop that ensures low levels of p53 in the absence of stress signaling (Michael and Oren, 2003).”
BackgroundBergh, J., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 460
Chemosensitivity linked to p73 function
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 408 · cited 1×
“Cisplatin has been shown to induce p73-dependent apoptosis (Irwin et al., 2003).”
BackgroundBørresen-Dale, A.-L. (2003) · Human Mutation · doi:10.1002/humu.10174 · Cited by 354
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Self-citationDrugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 697
Molecular Mechanisms of Apoptosis and Roles in Cancer Development and Treatment
Goldar, S., Khaniani, M. S., Derakhshan, S. M., & Baradaran, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2129 · Cited by 606
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Self-citationThe p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
“Importantly, PRIMA-1 and its structural analog PRIMA-1MET (APR-246) inhibited tumor growth in mouse models of GBM [124,129,130].”
BackgroundLehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Self-citationTP53 Mutations in Nonsmall Cell Lung Cancer
Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/583929 · Cited by 388
p53 and breast cancer, an update
Lacroix, M., Toillon, R.-A., & Leclercq, G. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01172 · Cited by 380
“The structural analogue MIRA3 shows anti-tumour activity in vivo against human mutant p53-carrying tumour xenografts in SCID mice (Bykov et al. 2005b).”
Backgroundp53 mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation
Li, X.-L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.84 · Cited by 367
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
p53 Family and Cellular Stress Responses in Cancer
Pflaum, J., Schlosser, S., & Müller, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00285 · Cited by 291
“PRIMA-1MET alone and PRIMA-1MET in combination with chemotherapeutic drugs are effective at inducing tumor cell apoptosis in vivo (221, 222, 225).”
BackgroundSoussi, T., & Wiman, K. G. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.53 · Cited by 305
“example, adriamycin and cisplatin, to induce mutant p53dependent tumor cell death.(82) Both PRIMA-1 and APR-246 are converted to the Michael acceptor methylene quinuclidinone (MQ) that binds covalently to cysteines in the p53 core domain(83) MQ binding to p53 is sufficient for mutant p53 reactivation, as shown by prot…”
BackgroundSelf-citationThe rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
Mitra, A. P., Datar, R. H., & Cote, R. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2073 · Cited by 284
Farnebo, M., Bykov, V. J. N., & Wiman, K. G. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.152 · Cited by 268
Self-citationAPR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261
Self-citationTargeting p53 for Novel Anticancer Therapy
Wang, Z., & Sun, Y. (2010) · Translational Oncology · doi:10.1593/tlo.09250 · Cited by 250
“[89] Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, and”
BackgroundLane, D. P., Cheok, C. F., & Lain, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 246
“Because of its positive effect on animal models and efficient killing of tumor cells in ex vivo experiments, PRIMA-1 (or APR-246, a more efficient analog of PRIMA-1 [Bykov et al. 2005]) is being tested in a Phase I clinical trial.”
BackgroundArsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Chen, S., Wu, J.-L., Liang, Y., Tang, Y.-G., Song, H.-X., Wu, L.-L., Xing, Y.-F., Yan, N., Li, Y.-T., Wang, Z.-Y., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.013 · Cited by 241
Mutant p53 in cancer therapy—the barrier or the path
Zhou, X., Hao, Q., & Lu, H. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy072 · Cited by 245
“Of note, APR-246 displays a synergistic inhibitory effect on tumor growth in combination of several commonly used chemotherapeutic drugs (Bykov et al., 2005).”
BackgroundMYC in Oncogenesis and as a Target for Cancer Therapies
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)07006-5 · Cited by 242
p53 as a target for the treatment of cancer
Duffy, M. J., Synnott, N. C., McGowan, P. M., Crown, J., O’Connor, D., & Gallagher, W. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.004 · Cited by 229
“Further work showed that PRIMA-1, as well as its more active methylated derivative, PRIMA-1MET [28] inhibited growth of several different types of mutant p53-expressing malignant cells in culture, as well as xenograft tumors in animal models [28–35].”
BackgroundMutant p53 in breast cancer: potential as a therapeutic target and biomarker
Duffy, M. J., Synnott, N. C., & Crown, J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4753-7 · Cited by 235
“The pro-apoptotic activity and membrane permeability of PRIMA-1 was subsequently enhanced by the addition of a methyl group, giving rise to the compound known as PRIMA-1MET or APR-246 [28].”
BackgroundMutant p53 in Cancer Progression and Targeted Therapies
Zhu, G., Pan, C., Bei, J.-X., Li, B., Liang, C., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 218
“While methylene quinuclidinone (MQ) is the common bioactive decomposition product of both APR-246 and PRIMA-1, the bioactivity of APR246 is much higher, possibly due to its higher lipophilicity and cell permeability (80, 82).”
BackgroundTumour suppression by p53: the importance of apoptosis and cellular senescence
Zuckerman, V., Wolyniec, K., Sionov, R. V., Haupt, S., & Haupt, Y. (2009) · The Journal of Pathology · doi:10.1002/path.2584 · Cited by 170
Jin, J.-K., Wu, K., Liu, X.-Y., Huang, G.-Q., Huang, Y.-L., Luo, D., Xie, M., Zhao, Y., Lu, W., Zhou, X.-P., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c10008 · Cited by 222
New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy
Long, J. S., & Ryan, K. M. (2012) · Oncogene · doi:10.1038/onc.2012.7 · Cited by 214
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 194
“p53 reactivation and induction of massive apoptosis-1 (PRIMA-1), and its optimized derivative PRIMA-1, were identified as compounds that specifically inhibited the growth of p53 mutant tumor cells [160,161].”
BackgroundTargeting protein–protein interactions: Lessons from p53/MDM2
Murray, J. K., & Gellman, S. H. (2007) · Peptide Science · doi:10.1002/bip.20741 · Cited by 186
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Self-citationAPR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Self-citationAPR-246 induces early cell death by ferroptosis in acute myeloid leukemia
Birsen, R., Larrue, C., Decroocq, J., Johnson, N., Guiraud, N., Gotanegre, M., Cantero-Aguilar, L., Grignano, E., Huynh, T., Fontenay, M., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.259531 · Cited by 182
Mutant p53 reactivation by small molecules makes its way to the clinic
Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 162
Self-citationPeng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
Self-citationTargeting the DNA Damage Response in OSCC with TP 53 Mutations
Lindemann, A., Takahashi, H., Patel, A. A., Osman, A. A., & Myers, J. N. (2018) · Journal of Dental Research · doi:10.1177/0022034518759068 · Cited by 162
“PRIMA-1 and its derivative, PRIMA-1met, specifically bind to several mutant p53 proteins and interact with the DNA-binding domain, thereby promoting proper folding of mutant proteins and restoration of some wtp53 functions (Bykov et al. 2005).”
BackgroundPharmacological reactivation of mutant p53: from protein structure to the cancer patient
Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 134
Self-citationOne, two, three—p53, p63, p73 and chemosensitivity
MULLER, M., Schleithoff, E. S., Stremmel, W., Melino, G., Krammer, P. H., & Schilling, T. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2007.01.001 · Cited by 165
TP53 in bone and soft tissue sarcomas
Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 149
Bykov, V. J. N., Zhang, Q., Zhang, M., Ceder, S., Abrahmsen, L., & Wiman, K. G. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00021 · Cited by 137
“Second, treatment with cisplatin, adriamycin, or 5-FU leads to accumulation of mutant p53 (17, 39), which is expected to enhance the effect of APR-246.”
BackgroundSelf-citationTargeting p53 for enhanced radio- and chemo-sensitivity
Lü, C., & El‐Deiry, W. S. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0330-1 · Cited by 151
Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3168 · Cited by 118
Self-citationStrategies for therapeutic targeting of the p53 pathway in cancer
Wiman, K. G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401921 · Cited by 149
Self-citationPeng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J., Arnér, E. S., & Wiman, K. G. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.137 · Cited by 134
Self-citationPerdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126
“The main reported mechanism to explain the PRIMA-1/APR-246 induced cell death was the induction of apoptosis, evaluated using common methods such DNA fragmentation [8,28,50,65], morphologic modifications [35,52,68], APO2.”
BackgroundMethodInfluentialThe Function of the Mutant p53-R175H in Cancer
Chiang, Y.-T., Chien, Y.-C., Lin, Y.-H., Wu, H.-H., Lee, D.-F., & Yu, Y.-L. (2021) · Cancers · doi:10.3390/cancers13164088 · Cited by 117
p53 as a hub in cellular redox regulation and therapeutic target in cancer
Eriksson, S. E., Ceder, S., Bykov, V. J. N., & Wiman, K. G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz005 · Cited by 123
“In agreement with this idea, APR-246 has been shown to synergize with chemotherapeutic drugs such as adriamycin and cisplatin (Bykov et al., 2005; Mohell et al., 2015).”
BackgroundSelf-citationMutant p53 targeting by the low molecular weight compound STIMA‐1
Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 96
Self-citationPharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases
Tao, Y.-X., & Conn, P. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00029.2016 · Cited by 115
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
Vanaja, D. K., Ballman, K. V., Morlan, B. W., Cheville, J. C., Neumann, R. M., Lieber, M. M., Tindall, D. J., & Young, C. Y. F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2072 · Cited by 118
p53-A natural cancer killer: Structural insights and therapeutic concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Buchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 93
Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
Synnott, N. C., Murray, A., McGowan, P. M., Kiely, M., Kiely, P. A., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., & Duffy, M. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30425 · Cited by 124
“A methylated derivative of PRIMA-1, dubbed PRIMA-1 or APR-246, was later synthesized and shown to be a stronger inducer of apoptosis than the parent compound (9).”
BackgroundMethodInfluentialMutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
Lambert, J. M. R., Moshfegh, A., Hainaut, P. L., Wiman, K. G., & Bykov, V. J. N. (2009) · Oncogene · doi:10.1038/onc.2009.425 · Cited by 121
Self-citationGain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Schulz‐Heddergott, R., & Moll, U. M. (2018) · Cancers · doi:10.3390/cancers10060188 · Cited by 117
Cheng, J., Fan, Y.-H., Xu, X. Y., Zhang, H., Dou, J., Tang, Y., Zhong, X., Rojas, Y., Yu, Y., Zhao, Y., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.54 · Cited by 107
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 113
Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
Li, H., Zhang, J., TONG, J. H. M., Chan, A. W. H., Yu, J. Q., Kang, W., & To, K. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235999 · Cited by 114
PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Saha, M. N., Jiang, H., Yang, Y., Reece, D., & Chang, H. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1166 · Cited by 91
Yan, X., Fraser, M. E., Qiu, Q., & Tsang, B. K. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.033 · Cited by 106
“Moreover, PTEN over-expression could potentially be used in combination with p53 gene therapy, or with other efforts to restore normal p53 function, as has been performed using pharmacological agents such as PRIMA [43].”
Regulation of Programmed Cell Death by the P53 Pathway
Kuribayashi, K., & El‐Deiry, W. S. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_10 · Cited by 110
Mutant p53: One, No One, and One Hundred Thousand
Walerych, D., Lisek, K., & Sal, G. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00289 · Cited by 100
Liu, D. S. H., Read, M. D., Cullinane, C. M., Azar, W. J., Fennell, C. M., Montgomery, K. G., Haupt, S., Haupt, Y., Wiman, K. G., Duong, C. P., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309770 · Cited by 94
Self-citationRoh, J., Kang, S. K., Minn, I., Califano, J. A., Sidransky, D., & Koch, W. M. (2010) · Oral Oncology · doi:10.1016/j.oraloncology.2010.10.011 · Cited by 102
Rangel, L. P., Ferretti, G. D. S., Costa, C. L., Andrade, S. M. M. V., Carvalho, R. S., da Costa, D. C. F., & Silva, J. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004671 · Cited by 96
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
Terra, S. B. S. P., Jang, J. S., Bi, L., Kipp, B. R., Jen, J., Yi, E. S., & Boland, J. M. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.89 · Cited by 90
Deben, C., Deschoolmeester, V., Lardon, F., Rolfo, C. D., & Pauwels, P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.019 · Cited by 90
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 92
p53 and retinoblastoma pathways in bladder cancer
Mitra, A. P., Birkhahn, M., & Côté, R. J. (2007) · World Journal of Urology · doi:10.1007/s00345-007-0197-0 · Cited by 93
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 86
“The most promising small molecule mutant reactivator to date and the only one of this kind to advance to clinical trials is APR-246 (also known as PRIMA-1MET), as APR-246 has completed a phase I trial for refractory hematologic prostate cancer (NCT00900614) and is currently recruiting for a study examining its efficac…”
BackgroundInfluentialTranslational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
Zhang, S., Carlsen, L., Borrero, L. J. H., Seyhan, A. A., Tian, X., & El‐Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 82
Targeting Mutant p53 in Human Tumors
Lehmann, B. D., & Pietenpol, J. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0412 · Cited by 72
Escape from immune- and nonimmune-mediated tumor surveillance
Malmberg, K., & Ljunggren, H. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.007 · Cited by 79
Haffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73
Self-citationTal, P., Eizenberger, S., Cohen, E., Goldfinger, N., Pietrokovski, S., Oren, M., & Rotter, V. (2016) · Oncotarget · doi:10.18632/oncotarget.7857 · Cited by 70
“Two small molecules that rescue p53 function in cancer cells, PRIMA-1 and MIRA-1, were identified using cell-based screening assays [40, 41], and were shown to activate mutp53 through binding free cysteine residues.”
BackgroundOncogenic Intra-p53 Family Member Interactions in Human Cancers
Ferraiuolo, M. A., Agostino, S. D., Blandino, G., & Strano, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00077 · Cited by 80
Synnott, N. C., Bauer, M. R., Madden, S. F., Murray, A. M., Klinger, R. W., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., Fersht, A. R., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.053 · Cited by 72
PRIMA-1MET Inhibits Growth of Mouse Tumors Carrying Mutant p53
Zache, N., Lambert, J. M. R., Wiman, K. G., & Bykov, V. J. N. (2008) · Analytical Cellular Pathology · doi:10.1155/2008/527939 · Cited by 77
Self-citationTargeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
Shen, J., Wang, Q., Mao, Y., Gao, W., & Duan, S. (2023) · MedComm · doi:10.1002/mco2.288 · Cited by 62
Izetti, P., Hautefeuille, A. H., Abujamra, A. L., de Farias, C. B., Giacomazzi, J., Alemar, B., Lenz, G., Roesler, R., Schwartsmann, G., Osvaldt, A. B., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0090-9 · Cited by 78
“PRIMA-1 has already been used in xenograft mouse models, with a good correlation between data obtained in cell cultures and in the xenografts [16, 18, 37], but no studies have been performed to confirm its effects on mouse models of pancreatic cancer.”
BackgroundP53 in skin cancer: From a master player to a privileged target for prevention and therapy
Loureiro, J. B., Abrantes, A. M., Oliveira, P. A., & Saraiva, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188438 · Cited by 81
Targeting mutant p53: a key player in breast cancer pathogenesis and beyond
Qayoom, H., Haq, B. U., Sofi, S., Jan, N., Jan, A., & Mir, M. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01863-9 · Cited by 77
“…is comprised chiefly of immune cells, ECM, stromal cells, and blood vessels displays a significant role in the process of carcinogenesis and drug resistance abilities [47, 48]; And mutp53 can regulate the TME by prompting the secretion of pro-inflammatory cytokines as well as angiogenesis [49, 50].”
BackgroundPRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
Stimulation of Suicidal Erythrocyte Death by PRIMA-1
Faggio, C., Alzoubi, K., Calabrò, S., & Lang, F. J. W. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000369717 · Cited by 67
TP53 in Biology and Treatment of Osteosarcoma
Synoradzki, K. J., Bartnik, E., Czarnecka, A. M., Fiedorowicz, M., Firlej, W., Brodziak, A., Stasinska, A., Rutkowski, P. L., & Grieb, P. (2021) · Cancers · doi:10.3390/cancers13174284 · Cited by 69
Fransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65
Self-citationThe role of the MDM2/p53 axis in antitumor immune responses
Brummer, T., & Zeiser, R. (2024) · Blood · doi:10.1182/blood.2023020731 · Cited by 60
Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1
Hang, W., Yin, Z.-X., Liu, G., Zeng, Q., Shen, X., Sun, Q., Li, D., Jian, Y., Zhang, Y.-H., Wang, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0110-2 · Cited by 67
Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma
Chen, H., Gotimer, K. F., Souza, C. D., Tepper, C. G., Karnezis, A. N., Leiserowitz, G. S., CHIEN, J. R., & Smith, L. H. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.03.026 · Cited by 67
Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments
de Bakker, T., Journé, F., Descamps, G., Saussez, S., Dragan, T., Ghanem, G., Krayem, M., & Gestel, D. V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.799993 · Cited by 70
“It is thought that reinstating the WT conformation of p53 may sensitize the cell to chemotherapeutics (54).”
BackgroundStructural and Drug Targeting Insights on Mutant p53
Gomes, A. S., Ramos, H., Inga, A., Sousa, E., & Saraiva, L. (2021) · Cancers · doi:10.3390/cancers13133344 · Cited by 67
Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein, Y., Aloni-Grinstein, R., & Rotter, V. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa117 · Cited by 63
Deben, C., Lardon, F., Wouters, A., de Beeck, K. O., den Bossche, J. V., Jacobs, J., Steen, N. V. D., Peeters, M., Rolfo, C. D., Deschoolmeester, V., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.017 · Cited by 61
Alhosin, M., Ibrahim, A., Boukhari, A., Sharif, T., Gies, J., Auger, C., & Schini‐Kerth, V. B. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9734-1 · Cited by 60
“Indeed, several studies have proposed that p73 is a novel promising target for cancer therapy [22–26].”
BackgroundPRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
Rökaeus, N., Shen, J., Eckhardt, I., Bykov, V. J. N., Wiman, K. G., & Wilhelm, M. (2010) · Oncogene · doi:10.1038/onc.2010.382 · Cited by 59
Self-citationDeben, C., Deschoolmeester, V., Waele, J. D., Jacobs, J., den Bossche, J. V., Wouters, A., Peeters, M., Rolfo, C. D., Smits, E., Lardon, F., et al. (2018) · Cancers · doi:10.3390/cancers10040126 · Cited by 62
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
Demir, S., Boldrin, E., Sun, Q., Hampp, S., Tausch, E., Eckert, C., Ebinger, M., Handgretinger, R., Kronnie, G. T., Wiesmüller, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.199364 · Cited by 64
Self-citationMessina, R. L., Sanfilippo, M., Vella, V., Pandini, G., Vigneri, P. G., Nicolosi, M. L., Gianì, F., Vigneri, R., & Frasca, F. (2011) · International Journal of Cancer · doi:10.1002/ijc.26228 · Cited by 57
Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
Bassett, E. A., Wang, W., Rastinejad, F., & El‐Deiry, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1526 · Cited by 62
Metadata
- Authors
- Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G.
- Affiliations
- Karolinska Institutet (SE)
- Corresponding author
- Wiman, Klas G
- Venue
- Oncogene
- Published
- 2005-02-28
- Volume
- 24
- Issue
- 21
- Pages
- 3484-3491
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2006422601
- Cited by
- 252
- References
- 19
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 16 · 2021: 21 · 2020: 14 · 2019: 12 · 2018: 18 · 2017: 7 · 2016: 16 · 2015: 11 · 2014: 7 · 2013: 9 · 2012: 11
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cancerfonden
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- mutant p53 reactivation, cisplatin, drug synergy, apoptosis, chemoresistance, combination chemotherapy, xenograft tumor growth, SCID mice
- MeSH terms
- Adenocarcinoma, Animals, Aza Compounds, Bone Neoplasms, Carcinoma, Non-Small-Cell Lung, Cisplatin, Drug Interactions, Humans, Lung Neoplasms, Mutation, Quinuclidines, Osteosarcoma, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Mice, SCID, Apoptosis, Drug Resistance, Neoplasm, Bridged Bicyclo Compounds, Heterocyclic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.